2022 Drug Discovery Conference

Welcome to 2022 Stanford Drug Discovery Symposium. This symposium provides a valuable and important platform for inspiring interdisciplinary exchange at the forefront of drug research and will support a fantastic networking experience. It provides a great resource for researchers, pharmaceutical companies, investment groups, and those in the wider biomedical community interested in discovering new drugs and improving patient care. We look forward to an exciting two days of talks and discussion.

— Joseph C. Wu, MD, PhD | Director, Cardiovascular Institute

Lifetime Achievement Awardee

Katalin Karikó, PhD

Senior VP, BioNTech

Participants

Karen Akinsanya, PhD

President of R&D, Therapeutics
Schrödinger

James (Jay) Bradner, MD

President
Novartis Institutes for BioMedical Research

Hogene L. Choi, JD

Partner
Morrison & Foerster, LLP

Myrtle Davis, DVM, PhD

Scientific Vice President, Discovery Toxicology
Bristol Myers Squibb

Kathy Giacomini, PhD

Prof of Bioengineering & Co-Dir UCSF-Stanford Center of Excellence in Regulatory Sciences and Innovation, UCSF

David Goel

Founder & Managing General Partner, Matrix Capital Management

Karin Immergluck, PhD

Executive Director
Stanford Office of Technology Licensing (OTL)

Daphne Koller, PhD

Founder & Chief Executive Officer
Insitro

Mathai Mammen, MD, PhD

Executive Vice President, Pharmaceuticals, R&D
Johnson & Johnson

Maria Millan, MD

President and Chief Executive Officer, CIRM

Merdad Parsey, MD, PhD

Chief Medical Officer, Gilead

Madhuri Roy, PhD, JD

Partner, Patent Counseling & Prosecution
Cooley

Marc Tessier-Lavigne, PhD

President and Bing Presidential Professor
Stanford University

Steve Artandi, MD, PhD

Laurie Kraus Lacob Director (SCI); Jerome and Daisy Low Gilbert Professor (Med and Biochem), Stanford

Amy L. Chang

Board of Directors at The Walt Disney Co, Procter & Gamble, Marqeta, and Pragma Platform

Jacqueline Corrigan-Curay, JD, MD

Principal Deputy Center Director
FDA, CDER

Ray Deshaies, PhD

Senior Vice President, Global Research
Amgen

Gary Gibbons, MD

Director, NHLBI

Aida Habtezion, MD

Chief Medical Officer and Head of Worldwide Medical & Safety
Pfizer

Joe Jimenez, MBA

Co-Founder and Managing Director
Aditum Bio

Dean Li, MD, PhD

Executive Vice President and President of Merck Research Laboratories

Peter Marks, MD, PhD

Director, Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

Lloyd Minor, MD

Carl and Elizabeth Naumann Professorship for the Dean, Stanford School of Medicine

Andrew Plump, MD, PhD

President, Research & Development
Takeda Pharmaceutical Company Limited

Alfred Sandrock, MD, PhD

CEO
Voyager Therapeutics

James Zou, PhD

Assistant Professor of Biomedical Data Science and, by courtesy, of CS and of EE
Stanford University

Claude Bertrand, PhD

Executive Vice President, Chief Scientific Officer, R&D
Servier

Margarita Chavez, JD

Managing Director
AbbVie Ventures

Lisa Coussens, PhD

Associate Director for Basic Research, Knight Cancer Institute, OHSU; and President, AACR

Carlos O. Garner, PhD

Vice President, Global Regulatory Affairs
Eli Lilly and Company

Christopher Gibson, PhD

Co-Founder, Chief Executive Officer of Recursion

Sandra J. Horning, MD

Board of Directors: Gilead, Moderna, & Olema Pharma.
Co-founder & Advisor, EQRx

Peter S. Kim, PhD

Virginia and D.K. Ludwig Professor of Biochemistry
Stanford University

Jonathan MacQuitty, PhD

Sector Head for Life Sciences
Lightspeed Ventures

Michelle McMurry-Heath, MD, PhD

President & CEO, Biotechnology Innovation Organization

Vern Norviel, JD

Partner, Patents and Innovations
Wilson Sonsini

Aviv Regev, PhD

Executive Vice President, Research and Early Development
Genentech

Randy Schekman, PhD

Professor of Molecular and Cell Biology, University of California, Berkeley; 2013 Nobel Laureate

Agenda

Monday, April 25, 2022

Start time: 9:00 am PST

9:00-9:15 am | Day 1 Introduction and Welcome

Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University

Lloyd Minor, MD
Dean, Stanford School of Medicine

Marc Tessier-Lavigne, PhD
President, Stanford University

9:15-9:55 am | Session I: Presentation of Lifetime Achievement Award

Moderator: Randy Schekman, PhD | Co-Moderator: Joseph C. Wu, MD, PhD

Randy Schekman, PhD
Professor of Molecular and Cell Biology, University of California, Berkeley | 2013 Nobel Laureate
Introduction of Katalin Karikó, PhD

Katalin Karikó, PhD
Senior Vice President, BioNTech
Awardee Lecture: Developing mRNA for therapy

Q&A

9:55-10:05 am

Break

10:05-11:20 am | Session II: Research Development I

Moderator: Myrtle Davis, DVM, PhD | Co-Moderator: Mark Mercola, PhD

Claude Bertrand, PhD
Executive Vice President, Chief Scientific Officer, R&D, Servier
Servier: A New Paradigm for R&D through a significant Transformation Journey

Dean Li, MD, PhD
Executive Vice President and President of Merck Research Laboratories
The Balance of Computing Power and Human Intelligence

Ray Deshaies, PhD
Senior Vice President, Global Research, Amgen
Multispecific Molecular Medicines

Carlos O. Garner, PhD
Vice President, Global Regulatory Affairs, Eli Lilly and Company
How COVID Will Reshape Clinical Research

Panel Discussion

11:20-12:20 pm | Session III: Patent Law

Moderator: Karin Immergluck, PhD | Co-Moderator: Kuldev Singh, MD

Madhuri Roy, JD, PhD
Partner, Cooley
Getting your IP House In Order

Vern Norviel
Partner, Patents and Innovations, Wilson Sonsini
Drug Label Patent Extension

Hogene Choi, JD
Partner, Morrison & Foerster
Strategies for Protecting Software Innovation in Drug Discovery

Panel Discussion

12:20-12:45 pm

Break

12:45-2:05 pm | Session IV: Public Policy

Moderator: Steven Artandi, MD, PhD | Co-Moderator: Mark Mercola, PhD

Michelle McMurry-Heath, MD
President & Chief Executive Officer, Biotechnology Innovation Organization
The Distribution of Scientific Progress: The Social Justice Issue of our Age

Gary Gibbons, MD
Director, NHLBI
Accelerating the Cycle of Innovation for Drug Discovery to Prevent and Preempt Chronic Disease

Jacqueline Corrigan-Curay, JD, MD
Principal Deputy Center Director, FDA, CDER
Evidence Generation – Enhancing Access and Equity

Maria Millan, MD
President and Chief Executive Officer, CIRM
CIRM: Building California's Public-Private Partnerships to Accelerate the Development of Cell and Gene Therapies

Panel Discussion

2:05–2:10 pm

Break

2:10-3:20 pm | Session V: Research Development II

Moderator: Sandra Horning, MD | Co-Moderator: Sanjay Malhotra, PhD

Alfred Sandrock, MD, PhD
CEO, Voyager Therapeutics
The Discovery and Development of Aducanumab for Alzheimer’s Disease

Lisa Coussens, MD
President, AACR; Associate Director for Basic Research, Knight Center Institute, Oregon Health & Science University
Neutralizing Protumor Inflammation: Lessons Learned from Preclinical Mouse Models

Randy Schekman, PhD
Professor of Molecular and Cell Biology, University of California, Berkeley | 2013 Nobel Laureate
Engineering a Membrane-Mediated Delivery of Genome Editing Functions

Panel Discussion

3:20-3:25 pm | Closing Remarks

Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University

Tuesday, April 26, 2022

Start time: 9:00 am PST

9:00-9:05 am | Day 2 Introduction and Welcome

Joseph Wu, MD, PhD
Director, Stanford Cardiovascular Institute; Simon H. Stertzer, MD, Professor of Medicine and Radiology, Stanford University

9:05-10:10 am | Session VI: Research Development III

Moderator: Kathleen Giacomini, PhD | Co-Moderator: Kuldev Singh, MD

Aida Habtezion, MD
Chief Medical Officer and Head of Worldwide Medical & Safety, Pfizer
Translating Lessons from the Covid-19 Programs

Mathai Mammen, MD, PhD
Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
Raising the Bar for Innovation

Peter Marks, MD, PhD
Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration
Facilitating the Development and Manufacturing of COVID-19 Vaccines

Panel Discussion

10:10–10:20 am

Break

10:20-10:50 am | Session VII: Fireside Chat with Katalin Karikó, PhD

Moderator: Dean Lloyd Minor, MD | Co-Moderator: Sanjay Malhotra, PhD

Katalin Karikó, PhD
Senior Vice President, BioNTech

Lloyd Minor, MD
Dean, Stanford School of Medicine

10:50-12:10 pm | Session VIII: Investing in Discovery

Moderator: Amy L. Chang, MSEE | Co-Moderator: Sanjay Malhotra, PhD

Joe Jimenez, MBA
Aditum Ventures
The Evolving Role of Venture Capital in the Pharma Ecosystem

David Goel
Founder & Managing General Partner, Matrix Capital Management
The Convergence of Technology and the Life Sciences

Jonathan MacQuitty, PhD
Sector Head for Life Sciences, Lightspeed Ventures
A New Approach to Healthcare Investing

Margarita Chavez, JD
Managing Director, AbbVie Ventures

Panel Discussion

12:10–12:40 pm

Break

12:40-1:40 pm | Session IX: Artificial Intelligence Technologies

Moderator: James Zou, PhD | Co-Moderator: Mark Mercola, PhD

Christopher Gibson, PhD
Co-Founder, Chief Executive Officer, Recursion
Mapping and Navigating Biology at Scale

Daphne Koller, PhD
Founder & Chief Executive Officer, Insitro
Transforming Drug Discovery using Digital Biology

Karen Akinsanya, PhD
Chief Biomedical Scientist, Schrödinger
Transitioning from Computer-aided and Empirical Drug Discovery to Computer-driven and Structure-based Drug Discovery

Panel Discussion

1:40–1:50 pm

Break

1:50-3:05 pm | Session X: Research Development IV

Moderator: Peter Kim, PhD | Co-Moderator: Kuldev Singh, MD

Andrew Plump, MD, PhD
President, R&D, Takeda Pharmaceutical
Creating a Patient-driven, Science-first R&D Organization

Aviv Regev, PhD
Executive Vice President, Research and Early Development, Genentech
Multiplicative Levers for Drug Discovery and Early Development

James (Jay) Bradner, MD
President, Novartis Institutes of BioMedical Research
New Paradigms in Therapeutics

Merdad Parsey, MD, PhD
Chief Medical Officer, Gilead
Development of Treatments for the Globe: from HIV to COVID-19

Panel Discussion